Veterinarians
By The Allibre Team · November 16, 2026

Allibre's Pilot Study: IgE Reductions Across Three Allergens

Weimaraner resting in a field of tall grass at sunset, surrounded by the grass pollens the pilot study measured

Allibre's headline figure, a 68% reduction in D. farinae-specific IgE, comes from a pilot study that measured more than one allergen. The study cream contained three: dust mite, ragweed, and Timothy grass. All three showed significant IgE reductions, alongside measurable improvement in lesion scores. Here's the full picture, including the study's limits.

Key Takeaways

  • Six dogs with atopic dermatitis and elevated allergen-specific IgE completed six months of transdermal immunotherapy.
  • Allergen-specific IgE fell 68% for dust mite, 53.8% for Timothy grass, and 43.5% for ragweed (p < 0.001 across all three).
  • CADESI-4 lesion scores decreased by an estimated 2.42 points per month.
  • IgG was unchanged, which the authors interpret as consistent with desensitization rather than broad immunosuppression.

How the Study Was Designed

The study, Evaluation of Antibody Levels and Clinical Response to Transdermal Immunotherapy in Dogs, was conducted by R. Muse and A. Rosenberg of Animal Dermatology Group and J. Nicholas of Stallergenes Greer. Six dogs with atopic dermatitis and elevated allergen-specific IgE were treated with a transdermal immunotherapy cream containing three allergens:

  • Dust mite (Dermatophagoides farinae)
  • Ragweed (Ambrosia artemisiifolia)
  • Timothy grass (Phleum pratense)

Serum IgE and IgG and CADESI-4 scores were measured at baseline and after one, three, and six months. IgE was analyzed with repeated-measures ANOVA and Tukey's HSD, and CADESI-4 was modeled with linear mixed effects.

IgE Results by Allergen

AllergenBaseline IgEMonth 6 IgEReduction
Dust mite (D. farinae)2292 EAU732 EAU68%
Timothy grass195 EAU90 EAU53.8%
Ragweed200 EAU113 EAU43.5%

The reductions were statistically significant for all three allergens (p < 0.001), and ANOVA confirmed significant differences in IgE levels over time (p = 0.0015). The fact that all three allergens moved in the same direction, from very different starting levels, matters as much as any single number. Dust mite IgE started more than ten times higher than the two pollens and still fell the most.

Clinical Response: CADESI-4

Lab values only matter if the patient improves. Alongside the IgE results, CADESI-4 lesion severity decreased by an estimated 2.42 points per month (95% CI −3.27 to −1.58). Because the whole confidence interval sits below zero, the improvement is unlikely to be a chance finding. CADESI-4 is the validated scoring system used throughout veterinary dermatology research. The CADESI-4 validation study explains how it scores 20 body sites for erythema, lichenification, and excoriation or alopecia, and our CADESI-4 explainer walks through using it in practice.

Why Unchanged IgG Matters

IgG stayed level throughout the study while allergen-specific IgE fell. The authors interpret that as consistent with desensitization rather than broad immunosuppression. In other words, the immune response to the treated allergens changed without the immune system being dampened overall. That's the distinction between immunotherapy and symptomatic drugs that work by suppressing parts of the immune or itch response.

What a Pilot Study Can and Can't Tell Us

Six dogs over six months is a pilot study, and it should be read as one. The results are promising and statistically significant, but a small sample can't establish response rates across a broad patient population, and six months is shorter than the year of treatment generally recommended before judging immunotherapy. The authors say this directly in their conclusion: transdermal immunotherapy reduced IgE levels and improved lesion severity, and further research with larger samples and longer treatment periods is warranted.

The pilot also sits within a wider body of research. Independent work on epicutaneous (through-the-skin) immunotherapy in dogs has explored the same delivery mechanism. See What the Research Says About Epicutaneous Immunotherapy for that context.

Read the Source

The one-page study abstract includes the full results and methods, and the Clinical Data page collects it with the other supporting documents. For how the protocol used in practice compares to the study schedule, see Inside the Allibre Protocol.

Common Questions

Why does unchanged IgG matter? Allergen-specific IgE fell while IgG stayed level. The study authors interpret that pattern as consistent with desensitization to the treated allergens rather than broad immunosuppression: the immune system wasn't simply turned down across the board.

Were the reductions statistically significant? Yes. The study reports statistically significant reductions in allergen-specific IgE across all three allergens (p < 0.001), and repeated-measures ANOVA confirmed significant differences in IgE levels over time (p = 0.0015).

Can I share the results with clients? Yes. The study abstract is available to download, and the Clinical Data page summarizes it in plain language. When sharing, it's worth mentioning that this was a small pilot study, as the authors themselves note.

Share this article
Ready to add Allibre to your treatment options?

See the full clinical data, then register your clinic to start ordering.

Start Ordering